The aberrant expression of the MDM2 oncogene, which functions as an E3 ubiquitin ligase that inhibits p53 by facilitating its proteasomal degradation, consequently limiting its tumor-suppressive capabilities, is observed in approximately 36.6% of primary NB cases [13,37]. The gene discussed is MDM2; the disease is neuroblastoma.